Altimmune Valuation

Is 0A4C undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0A4C when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0A4C's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0A4C's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0A4C?

Key metric: As 0A4C barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0A4C. This is calculated by dividing 0A4C's market cap by their current book value.
What is 0A4C's PB Ratio?
PB Ratio4.9x
BookUS$133.38m
Market CapUS$647.95m

Price to Book Ratio vs Peers

How does 0A4C's PB Ratio compare to its peers?

The above table shows the PB ratio for 0A4C vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average43.8x
PRTC PureTech Health
1.6x-13.0%UK£397.4m
OXB Oxford Biomedica
6.8x92.5%UK£451.8m
GNS Genus
2x36.9%UK£1.1b
FARN Faron Pharmaceuticals Oy
164.7x11.4%UK£188.3m
0A4C Altimmune
4.9x18.6%US$647.9m

Price-To-Book vs Peers: 0A4C is expensive based on its Price-To-Book Ratio (4.9x) compared to the peer average (4.2x).


Price to Book Ratio vs Industry

How does 0A4C's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.5x101.0%US$3.71m
VAL ValiRx
0.5xn/aUS$2.53m
No more companies available in this PB range
0A4C 4.9xIndustry Avg. 2.9xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0A4C is expensive based on its Price-To-Book Ratio (4.9x) compared to the UK Biotechs industry average (2.9x).


Price to Book Ratio vs Fair Ratio

What is 0A4C's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0A4C PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0A4C's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0A4C forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$9.22
US$21.25
+130.4%
29.6%US$28.00US$10.00n/a8
Dec ’25US$8.57
US$21.25
+148.0%
29.6%US$28.00US$10.00n/a8
Nov ’25US$6.74
US$20.57
+205.2%
31.4%US$28.00US$10.00n/a7
Oct ’25US$6.48
US$20.57
+217.7%
31.4%US$28.00US$10.00n/a7
Sep ’25US$6.67
US$20.57
+208.4%
31.4%US$28.00US$10.00n/a7
Aug ’25US$6.13
US$20.57
+235.9%
31.4%US$28.00US$10.00n/a7
Jul ’25US$7.03
US$20.57
+192.6%
31.4%US$28.00US$10.00n/a7
Jun ’25US$7.19
US$20.57
+186.1%
31.4%US$28.00US$10.00n/a7
May ’25US$7.17
US$21.86
+204.8%
35.5%US$35.00US$11.00n/a7
Apr ’25US$10.29
US$21.25
+106.6%
34.6%US$35.00US$12.00n/a8
Mar ’25US$12.14
US$21.75
+79.2%
31.1%US$35.00US$13.00n/a8
Feb ’25US$10.05
US$21.75
+116.5%
31.1%US$35.00US$13.00n/a8
Jan ’25US$11.32
US$22.29
+96.9%
30.8%US$35.00US$15.00n/a7
Dec ’24US$3.91
US$21.29
+444.1%
38.6%US$35.00US$8.00US$8.577
Nov ’24US$2.42
US$20.00
+726.7%
40.1%US$35.00US$10.00US$6.747
Oct ’24US$2.61
US$21.29
+715.5%
32.7%US$35.00US$15.00US$6.487
Sep ’24US$2.64
US$19.38
+634.2%
42.6%US$35.00US$6.00US$6.678
Aug ’24US$3.16
US$24.63
+679.4%
50.4%US$50.00US$6.00US$6.138
Jul ’24US$3.59
US$24.63
+586.3%
50.4%US$50.00US$6.00US$7.038
Jun ’24US$4.20
US$25.13
+498.4%
49.2%US$50.00US$6.00US$7.198
May ’24US$5.06
US$26.25
+418.8%
46.3%US$50.00US$6.00US$7.178
Apr ’24US$4.21
US$26.25
+523.7%
46.3%US$50.00US$6.00US$10.298
Mar ’24US$12.05
US$29.38
+143.8%
29.7%US$50.00US$20.00US$12.148
Feb ’24US$12.95
US$29.13
+125.0%
30.2%US$50.00US$20.00US$10.058
Jan ’24US$15.93
US$27.75
+74.2%
36.3%US$50.00US$14.00US$11.328
Dec ’23US$10.66
US$27.75
+160.4%
36.3%US$50.00US$14.00US$3.918

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies